(Q30662550)

26 June 2017

title

Identification of drug metabolites in human plasma or serum integrating metabolite prediction, LC-HRMS and untargeted data processing (English)

1 reference

26 June 2017

1 reference

Peter L Jacobs

1

1 reference

26 June 2017

Lars Ridder

2

1 reference

26 June 2017

Marco Ruijken

3

1 reference

26 June 2017

Hilde Rosing

4

1 reference

26 June 2017

Nynke Gl Jager

5

1 reference

26 June 2017

Jos H Beijnen

6

1 reference

26 June 2017

Richard R Bas

7

1 reference

26 June 2017

William D van Dongen

8

1 reference

26 June 2017

publication date

1 September 2013

1 reference

26 June 2017

1 reference

26 June 2017

volume

5

1 reference

26 June 2017

issue

17

1 reference

26 June 2017

page(s)

2115-2128

1 reference

Role of pharmacologically active metabolites in drug discovery and development

26 June 2017

cites work

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Idiosyncratic drug reactions: past, present, and future

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Sensitive and specific liquid chromatographic-tandem mass spectrometric assay for dihydroergotamine and its major metabolite in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Quantitation of the flavonoid wogonin and its major metabolite wogonin-7 beta-D-glucuronide in rat plasma by liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Identification and quantitative determination of benproperine metabolites in human plasma and urine by liquid chromatography-tandem mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Metabolites in safety testing

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

A holistic strategy for characterizing the safety of metabolites through drug discovery and development

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Progressing preclinical drug candidates: strategies on preclinical safety studies and the quest for adequate exposure

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: are they still necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

In silico methods for predicting metabolism and mass fragmentation applied to quetiapine in liquid chromatography/time-of-flight mass spectrometry urine drug screening

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Metabolic soft spot identification and compound optimization in early discovery phases using MetaSite and LC-MS/MS validation.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Computational prediction of metabolism: sites, products, SAR, P450 enzyme dynamics, and mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Analytical strategies for assessment of human metabolites in preclinical safety testing

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Investigational study of tamoxifen phase I metabolites using chromatographic and spectroscopic analytical techniques.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Bioanalytical methods for determination of tamoxifen and its phase I metabolites: a review

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Importance of highly selective LC-MS/MS analysis for the accurate quantification of tamoxifen and its metabolites: focus on endoxifen and 4-hydroxytamoxifen

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Metabolic disposition of [14C]bazedoxifene in healthy postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Metabolism and Disposition of [14C]BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor, after Oral Administration to Humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Disposition and metabolism of [14C]SB-649868, an orexin 1 and 2 receptor antagonist, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Pharmacokinetics and metabolism of 14C-brivaracetam, a novel SV2A ligand, in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Pharmacokinetics, distribution, and metabolism of [14C]sunitinib in rats, monkeys, and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Absorption, metabolism and excretion of [(14)C]mirabegron (YM178), a potent and selective β(3)-adrenoceptor agonist, after oral administration to healthy male volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Comparative metabolism of 14C-labeled apixaban in mice, rats, rabbits, dogs, and humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Disposition of [1'-(14)C]stavudine after oral administration to humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Disposition and metabolism of [14C]brasofensine in rats, monkeys, and humans

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Response normalized liquid chromatography nanospray ionization mass spectrometry

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Evaluation of relative LC/MS response of metabolites to parent drug in LC/nanospray ionization mass spectrometry: potential implications in MIST assessment

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Identification of a novel N-carbamoyl glucuronide: in vitro, in vivo, and mechanistic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Substructure-based annotation of high-resolution multistage MS(n) spectral trees

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Automatic chemical structure annotation of an LC-MS(n) based metabolic profile from green tea.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes.

21 January 2018

1 reference

https://api.crossref.org/works/10.4155%2FBIO.13.178

21 January 2018

Identifiers

DOI

10.4155/BIO.13.178

1 reference

26 June 2017

1 reference